34 results about "Cartilaginous Differentiation" patented technology

The invention discloses a genetically modified stem cell for cartilage repair treatment as well as a preparation method and application of the genetically modified stem cell, and further provides a pharmaceutical composition containing the stem cell. The stem cells comprise nucleic acid for coding an anti-inflammatory factor and nucleic acid for coding a cartilage repair factor, by simultaneously modifying the mesenchymal stem cells by adopting the anti-inflammatory factor and a factor for promoting cartilage differentiation, the mesenchymal stem cells can be effectively promoted to be differentiated into cartilage, and by comprehensively acting on various immune cells through combination of various factors, and the activity of various immune cells is inhibited, so that the local inflammatory environment problem of cartilage repair of parts such as bones and knees is solved, and the swelling condition of a clinical patient is reduced or decreased when the mesenchymal stem cells are applied to bone and knee repair.

The invention provides a preparation for mobilizing mesenchymal stem cells and a method for separating the mesenchymal stem cells. The preparation for mobilizing the mesenchymal stem cells comprises CoCl2, wherein the CoCl2 is a hypoxia mimetic agent, and the dosage is in a range of 5-20mg/kg. The CoCl2 and AMD3100 are used in a combined manner. The dosage of the AMD3100 is 5mg/kg. According to the method for separating the mesenchymal stem cells by using the preparation, the preparation is used for actuating the mesenchymal stem cells to be mobilized, enter peripheral blood and then be separated. The method comprises the following separation steps of: sampling the periphery blood, separating mononuclear cells by using a lymphocyte separating medium, performing resuspension by using a DMEM (dulbeccos modified eagle medium) containing 20% of fetal bovine serum, inoculating to a culture flask, culturing for 7 days, and changing a culture solution, thus obtaining the mesenchymal stem cells of the peripheral blood on the 10th day. The mesenchymal stem cells of the peripheral blood highly express CD90, CD29 and CD44, do not express CD45 and CD34, and have the capacities of in vitro bone formation, fat formation and cartilage differentiation formation. The preparation is high in MSCs (mesenchymal stem cells) mobilization efficiency, and an effective preparation and an effective method are provided for tissue engineering and regenerative medicine.

The invention provides mesenchymal stem cell membrane camouflaged magnetic drug-loaded nanoparticles as well as a preparation method and application thereof. The drug-loaded nanoparticles comprise drug-loaded Fe3O4 nanoparticles and a mesenchymal stem cell membrane compounded on the surfaces of the drug-loaded Fe3O4 nanoparticles, wherein the mass ratio of a drug to Fe3O4 nanoparticles in the drug-loaded Fe3O4 nanoparticles is 1:(4.5-5.5); the drug is selected from drugs capable of promoting cartilage differentiation and repair; and the ratio of the mass of the drug-loaded Fe3O4 nanoparticlesto the number of cell sources of the mesenchymal stem cell membrane is (3.4-3.9) mg: 5x10<6>. According to the drug-loaded nanoparticles, the mesenchymal stem cell membrane is taken as a carrier, andthe Fe3O4 nanoparticles loaded with the drug capable of promoting cartilage differentiation and repair are enveloped, so that the drug can be stably and efficiently transported to a diseased region, and the repair of cartilage tissues can be promoted. The mesenchymal stem cell membrane camouflaged magnetic drug-loaded nanoparticles are non-toxic, degradable and good in biocompatibility; and the effect of promoting cartilage repair is superior to that of pure local medication.

The invention belongs to the technical field of cartilage repair, and discloses a hydrogel material for promoting cartilage repair as well as a preparation method and application thereof. The preparation method comprises the following steps: pretreating BMSC (bone mesenchymal stem cells) by adopting TGF-beta3 to obtain TGF-beta3-miRNA-extracellular vesicles, co-culturing the BMSC and the TGF-beta3-miRNA-extracellular vesicles to obtain the BMSC of the TGF-beta3-miRNA-extracellular vesicles, and uniformly mixing the obtained product with hydrogel with biocompatibility to obtain the hydrogel material for promoting cartilage repair. According to the material, due to the synergistic effect of TGF-beta3-miRNA-extracellular vesicles, the limitation of promoting cartilage differentiation of BMSC by only using TGF-beta3 is overcome, the cartilage differentiation efficiency of BMSC is improved, and the material has a remarkable and excellent cartilage repair effect and can be applied to treatment of damaged cartilage.

The invention relates to the field of cells, in particular to a composition, differentiation inducing culturing liquid containing the composition and an inducing method. Selected dental pulp stem cells (dental pulp stem cell, DPSCs) are same with MSCs of other sources, have self-renewing and multi-directional differentiation capacity and have the advantages that cell proliferation in vitro is easy, and the immunogenicity of the cells is low, and the selected dental pulp stem cells can be taken as seed cells to promote repairing and regeneration of injured tissue. Thedifferentiation inducing culturing liquid can effectively promote specificity differentiation, towards cartilage cells, of DPSCs. Based on the differentiation inducing culturing liquid, the provided method ofchondrogenesisdifferentiation for the DPSCs subjected to in-vitro inducing culturingcan successively achieve chondrogenesis differentiation inducing on the DPSCs.

The invention discloses up-conversion nanoparticles and application thereof in light-operated induction of MSC (mesenchymal stem cell) cartilage differentiation and tracing imaging. According to the up-conversion nanoparticles, the surface of a mesoporous silicon layer is modified with cell-targeted polypeptide RGD. KGN and the up-conversion nanoparticles are stirred for reaction and centrifuged to obtain the KGN-loaded nano-composite. The nano-composite loaded with the KGN and MSC are co-incubated, and then the cells are irradiated by using near-infrared light to promote the nano-composite loaded with the KGN to release small drug molecules KGN to induce the MSC to be directionally differentiated into cartilage cells; and the differentiated MSC is traced and imaged through 545/647 nm fluorescence emitted by the up-conversion nanoparticles. The nano-composite disclosed by the invention has a cell targeting effect, and the drug KGN can be released only when 980nm near-infrared illumination exists outside, so that cartilage differentiation of stem cells is induced; and the cell imaging can be traced for a long time, and the positioning is provided for the MSC in the transplantation body.

The present invention refers to a method of manufacturing an implantable construct comprising chondrogenically differentiated cells and one or more polycaprolactone (PCL) microcarriers, an implantable construct produced using said method, and uses of the implantable construct. The present invention also refers to a method of manufacturing an implantable construct comprising mesenchymal stromal cells and one or more polycaprolactone (PCL) microcarriers, an implantable construct produced using said method, and uses of the implantable construct. The present invention further refers to a method of treating a disease or disorder associated with cartilage and/or bone defect, the method comprises administering one or more cell-free polycaprolactone (PCL) microcarriers in a patient suffering from the disease or disorder.

The present invention relates to a pharmaceutical composition for treating cartilage damage, the composition comprising nasal septum chondrocytes (NSCs) as an active ingredient, and a method for producing the NSCs into a spheroidal shape. The NSCs enable the expression of type II collagen which is a constituent component of cartilage, and SOX9 which is involved in chondrogenic differentiation, and an excellent cartilage treatment effect was shown as a result of administrating spheroidal NSCs to an animal model of cartilage damage, and thus the pharmaceutical composition and the method for producing the NSCs, according to the present invention, may be useful employed in the field of autologous chondrocyte implantation.

The invention discloses application of an AhR inhibitor in inducing chondrogenic differentiation of mesenchymal stem cells and treating related diseases. The invention finds that ginseng epoxy alkynol can promote proliferation and cartilage differentiation of umbilical cord mesenchymal stem cells by inhibiting AhR; therefore, the application of the culture medium to the in-vitro induced differentiation culture of the umbilical cord mesenchymal stem cells is helpful for overcoming the defects of weak proliferation capacity and differentiation capacity when the umbilical cord mesenchymal stem cells are induced to be differentiated into cartilage cells by a conventional method.